Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab vs XELOX in MSI-H or POLE/POLD1 Mutated Colon Cancer
NCT04969029Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in colon cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT04969029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969029.